Treatments for chronic myeloid leukemia in the accelerated phase

Last medical review:

The goal of treatment for chronic myeloid leukemia (CML) in the accelerated phase is to return it to the chronic phase. Your healthcare team will suggest treatments based on your needs and work with you to develop a treatment plan. During treatment they will check your blood and bone marrow to see how well CML is responding. Based on the results of these tests they may change your treatment.

The following are treatment options for CML in the accelerated phase.

Targeted therapy

Targeted therapy uses drugs to target specific molecules (such as proteins) on cancer cells or inside them to stop the growth and spread of cancer.

The targeted therapy drugs used to treat CML are called tyrosine kinase inhibitors (TKIs).

The TKI given will depend on if CML is newly diagnosed in the accelerated phase or if it has progressed from the chronic phase while you were taking TKIs.

Imatinib (Gleevec) may be continued at a higher dose if you were taking it in the chronic phase. It may also be given if CML doesn't respond to treatment with other TKIs.

Dasatinib (Sprycel), nilotinib (Tasigna) or bosutinib (Bosulif) is given if CML is diagnosed in the accelerated phase or if it has progressed from the chronic phase while you were taking imatinib.

Ponatinib (Iclusig) is given if there are other gene mutations in addition to the BCR-ABL gene, such as the T315I gene mutation.

Find out more about targeted therapy for CML.

Stem cell transplant

A stem cell transplant replaces stem cells. The type of transplant that may be offered for CML in the accelerated phase is called an allogeneic stem cell transplant. It uses stem cells from a donor.

You may be offered a stem cell transplant if treatment with TKIs moves the disease from the accelerated phase back to the chronic phase, or treatment improves blood counts. This is because there is a better chance that the transplant will be successful.

Find out more about a stem cell transplant for CML.

Clinical trials

Talk to your doctor about clinical trials open to people with CML in Canada. Clinical trials look at new ways to prevent, find and treat cancer. Find out more about clinical trials.

Expert review and references

  • Jeffrey H Lipton, PhD, MD, FRCPC
  • Guideline Resource Unit. Chronic Myeloid Leukemia. Alberta Health Services; 2020.
  • Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. American Journal of Hematology. 2020: 95:691-709.
  • PDQ® Adult Treatment Editorial Board. Chronic Myelogenous Leukemia Treatment (PDQ®) – Health Professional Version. Bethesda, MD: National Cancer Institute; March 5, 2021.
  • Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020: 34: 966-984.
  • Hehlmann R. The new ELN recommendations for treating CML. Journal of Clinical Medicine. 2020: 9(11):3671.
  • Smith G, Apperly J, Milojkovic D, Cross, NCP, Foroni L, et al. A British Society for Haematology guideline on the diagnosis and management of chronic myeloid leukaemia. British Journal of Haematology. 2020: 191: 171-193.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2024 Canadian Cancer Society